Key Points
- Director William Carson bought 8,000 Annexon shares at an average price of $5.78, spending $46,240 and increasing his direct ownership by 11.36% to 78,405 shares.
- Annexon recently reported quarterly EPS of ($0.23), which beat analyst expectations of ($0.30) by $0.07, while analysts now project a full-year loss of about $1.02 per share.
- Analyst sentiment remains mixed: Goldman Sachs started coverage with a neutral rating and a $7 price target, while the overall consensus on ANNX is Hold with a $16 target.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson acquired 8,000 shares of the company's stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $5.78 per share, for a total transaction of $46,240.00. Following the completion of the transaction, the director directly owned 78,405 shares of the company's stock, valued at approximately $453,180.90. This trade represents a 11.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Annexon Price Performance
Shares of ANNX opened at $5.45 on Thursday. The firm has a market capitalization of $892.93 million, a PE ratio of -4.47 and a beta of 1.22. The company's 50-day moving average is $5.70 and its 200-day moving average is $5.15. Annexon, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $7.18.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. Analysts predict that Annexon, Inc. will post -1.02 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Annexon
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. raised its position in shares of Annexon by 248.8% in the first quarter. Sei Investments Co. now owns 203,236 shares of the company's stock valued at $1,126,000 after buying an additional 144,977 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Annexon by 28.6% in the first quarter. Dimensional Fund Advisors LP now owns 924,078 shares of the company's stock valued at $5,115,000 after buying an additional 205,398 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Annexon in the first quarter valued at approximately $136,000. Swiss National Bank acquired a new stake in shares of Annexon in the first quarter valued at approximately $1,307,000. Finally, Bank of New York Mellon Corp raised its position in shares of Annexon by 9.2% in the first quarter. Bank of New York Mellon Corp now owns 395,019 shares of the company's stock valued at $2,188,000 after buying an additional 33,342 shares in the last quarter.
Analyst Ratings Changes
ANNX has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Annexon in a research report on Tuesday. They issued a "neutral" rating and a $7.00 price objective on the stock. Wall Street Zen raised shares of Annexon from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Annexon in a research report on Monday, April 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a research report on Wednesday, January 14th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $16.00 price target on shares of Annexon in a research report on Friday, March 20th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $16.00.
View Our Latest Research Report on ANNX
About Annexon
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
